Global Amyloidosis Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Amyloidosis Treatment Market

• The Global Amyloidosis Treatment Market size was valued at USD 5.15 Billion in 2024 and is expected to reach USD 9.60 Billion by 2032, at a CAGR of 8.10 % during the forecast period
• The market growth is primarily driven by the rising prevalence of amyloidosis (ATTR) worldwide, coupled with increased awareness and early diagnosis initiatives. Advancements in genetic testing and biomarker-based diagnostics are enabling faster identification and treatment initiation, propelling demand for innovative therapies.
• Additionally, increasing patient preference for disease-modifying therapies—particularly those that target the underlying pathology of amyloidosis—is driving demand across global markets. The emergence of novel RNA interference (RNAi) therapies and transthyretin (TTR) stabilizers is reshaping the treatment landscape. These innovations are positioning amyloidosis therapies at the forefront of rare disease management, catalyzing faster adoption and significantly accelerating global market growth.

Amyloidosis Treatment Market Analysis

• Amyloidosis is an ultra-rare metabolic disorder that affects the functionality and shape of organs and tissues. This can give rise to life threatening diseases. Amyloidosis generally develops when amyloid protein is deposited in the tissues and organs.
• The increasing demand for amyloidosis treatments is primarily driven by heightened disease awareness, advancements in diagnostic capabilities, and a growing patient population affected by both hereditary and wild-type forms of the disease. A surge in research and development activities is also contributing to improved therapeutic options and accessibility.
• North America is projected to lead the global amyloidosis treatment market, North America is expected to account for the largest revenue share of 40.01% in 2025. This dominance is supported by early adoption of novel therapeutics, higher healthcare spending, strong reimbursement structures, and the robust presence of major pharmaceutical players. The U.S., in particular, is witnessing significant growth due to the availability of approved therapies like tafamidis and the expansion of clinical trials.
• The Asia-Pacific region is anticipated to be the fastest-growing market during the forecast period, the Asia-Pacific region is driven by increasing urbanization, improving healthcare infrastructure, rising disposable incomes, and a growing focus on rare diseases. Countries such as China, Japan, and South Korea are investing heavily in early diagnosis and treatment access for amyloidosis.
• The tafamidis segment is expected to hold the largest market share of 43.2% in 2025, owing to its proven clinical efficacy, established safety profile, and status as the first FDA-approved treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM). Its oral administration route and effectiveness in delaying disease progression have made it the preferred therapeutic option among healthcare providers.

Report Scope and Amyloidosis Treatment Market Segmentation

Amyloidosis Treatment Market Trends

“Rising Adoption of Disease-Modifying Therapies as Standard of Care in Amyloidosis Treatment”

• A significant and accelerating trend in the global biopharmaceutical industry is the expansion of portfolios through strategic licensing agreements. These partnerships enable companies to diversify their product offerings, access innovative therapies, and enter new markets without the need for extensive in-house development. 
• For instance, Fresenius Kabi's licensing agreement with SamChunDang Pharm to commercialize an aflibercept biosimilar exemplifies this trend. By securing exclusive rights in the U.S. and several Latin American countries, Fresenius Kabi enhances its ophthalmic treatment portfolio and broadens its market presence
• Such strategic partnerships allow companies to leverage external innovations, reduce time-to-market for new therapies, and meet the growing demand for cost-effective treatment options in various therapeutic areas. 
• This trend is particularly pertinent in regions like India, where access to affordable healthcare solutions is crucial, and where partnerships can facilitate the introduction of advanced treatments to underserved populations.  
• The demand for advanced Amyloidosis Treatments integrating artificial intelligence and data-driven diagnostic tools is increasing globally, as healthcare providers and patients prioritize precision, early detection, and personalized therapeutic strategies. 

Amyloidosis Treatment Market Dynamics

Driver

“Rising Prevalence of Transthyretin Amyloidosis (ATTR) and Increased Diagnostic Rates”

• A key driver of growth in the Global Amyloidosis Treatment Market is the rising prevalence of transthyretin amyloidosis (ATTR), particularly among older adults, coupled with improvements in diagnostic capabilities. ATTR amyloidosis often remains underdiagnosed due to its nonspecific symptoms, but advanced imaging technologies and genetic testing are significantly improving detection rates.
• For instance, in February 2025, Alnylam Pharmaceuticals launched an awareness campaign across the U.S. and Europe promoting early cardiac screening for ATTR, which included subsidized diagnostic services in partnership with major hospitals. This initiative led to a measurable increase in confirmed ATTR diagnoses and greater uptake of treatments such as patisiran.
• The growing number of diagnosed cases, driven by technological advances like cardiac MRI and bone scintigraphy, is expanding the patient base eligible for therapies. This, in turn, increases demand for both gene-silencing drugs and TTR stabilizers that have shown efficacy in slowing disease progression.
• Moreover, heightened clinical awareness among cardiologists and neurologists, especially in high-risk populations such as those over 60, is reducing time to diagnosis. This trend is contributing to early therapeutic intervention, improving patient outcomes and bolstering the overall growth of the amyloidosis treatment market.

Restraint/Challenge

“High Treatment Costs and Limited Reimbursement Policies Restraining Market Growth”

• The high cost of Amyloidosis Treatments remains a significant restraint in the global market, limiting accessibility for many patients, especially in low- and middle-income countries. These advanced therapies, including gene silencers and stabilizers, often come with premium pricing due to complex development processes and regulatory requirements.
• For instance, the pricing of tafamidis, a leading Amyloidosis Treatment, has been a concern globally, with annual treatment costs reaching upwards of $200,000 in some regions, making it unaffordable for many patients and healthcare systems. Such high costs pose challenges to widespread adoption and reimbursement approvals.
• The financial burden on patients and insurers slows market penetration, particularly where healthcare coverage is limited. This situation underscores the need for more cost-effective treatment options and greater support programs from pharmaceutical companies.
• While efforts are underway to develop biosimilars and alternative therapies at lower price points, as well as patient assistance programs from companies like Pfizer and Akcea Therapeutics, the overall expense remains a key hurdle to broader market growth.

Amyloidosis Treatment Market Scope

The market is segmented on the basis of type, therapy type, treatment type, drugs, route of administration and end users.

• By Type

On the basis of type, the Global Amyloidosis Treatment Market is segmented into primary amyloidosis, secondary amyloidosis, dialysis-related amyloidosis and others. The primary amyloidosis segment dominates with the largest market revenue share of 43.2% in 2025, driven by the effectiveness of therapies such as tafamidis, which stabilize transthyretin proteins and help delay disease progression. The drug's well-established safety, oral dosing, and ease of administration contribute significantly to its widespread use and patient adherence.

The primary amyloidosis segment is also projected to witness the fastest compound annual growth rate (CAGR) of 21.7% between 2025 and 2032, propelled by its expanding therapeutic role in both hereditary and wild-type transthyretin amyloidosis cases. Improved diagnostic capabilities, increased physician awareness, and a rising patient base are contributing factors fueling rapid market growth in this segment.

• By Therapy Type

On the basis of therapy type, the Amyloidosis Treatment market is segmented into chemotherapy and targeted therapy. The chemotherapy segment held the largest market revenue share in 2025, driven by its clinical efficacy in reducing abnormal plasma cell production in patients with AL amyloidosis. Chemotherapy remains a cornerstone in treatment, particularly in combination with stem cell transplantation, and is supported by long-standing clinical evidence and physician familiarity.

The chemotherapy segment is expected to witness the fastest CAGR from 2025 to 2032, driven by increasing global diagnosis rates, improved access to oncology care, and growing awareness of amyloidosis as a plasma cell disorder. The continued development of safer and more tolerable chemotherapeutic regimens further supports its role in enhancing treatment outcomes and broadening patient reach.

• By Treatment Type

On the basis of Treatment Type, the Amyloidosis Treatment market is segmented into medication and surgery. The medication held the largest market revenue share in 2025, driven by the ubiquitous use of smartphones and the convenience of managing access through dedicated mobile applications. Medication offers features such as remote access, digital key sharing, and activity logs, making it a highly versatile and user-friendly option.

The medication is expected to witness the fastest CAGR from 2025 to 2032, favored for its reliability and the ability to grant access using PIN codes, providing a convenient alternative to physical keys or smartphones. Keypads are particularly popular in rental properties and for providing access to service personnel.

• By Drugs

On the basis of drugs, the Amyloidosis Treatment market is segmented into transthyretin transport inhibitors, immunomodulatory drugs, monoclonal antibodies, proteasome inhibitors, and others. The transthyretin transport inhibitor segment accounted for the largest market revenue share in 2024, driven by increasing awareness of amyloidosis and the proven efficacy of drugs like tafamidis in stabilizing transthyretin proteins to slow disease progression. Growing patient preference for targeted therapies and expanded approvals are key growth factors.

The transthyretin transport inhibitor segment is expected to witness the fastest CAGR from 2025 to 2032, fueled by ongoing research advancements, expanding indications in hereditary and wild-type amyloidosis, and rising accessibility of novel therapeutics in emerging markets. Enhanced patient outcomes and favorable reimbursement policies further boost adoption of this drug class.

Amyloidosis Treatment Market Regional Analysis

• North America dominates the Amyloidosis Treatment market with the largest revenue share of 40.01% in 2024, driven by increasing disease awareness, advanced healthcare infrastructure, and strong investments in research and development.
• Patients and healthcare providers in the region prioritize early diagnosis and access to innovative therapies, supported by robust reimbursement frameworks and widespread availability of approved treatments like tafamidis.
• This leadership is further reinforced by high healthcare expenditure, growing geriatric population, and the presence of major pharmaceutical companies, making North America a key market for both hereditary and wild-type amyloidosis management.

U.S. Amyloidosis Treatment Market Insight

The U.S. Amyloidosis Treatment market accounted for the largest revenue share of 81% within North America in 2025, driven by increasing awareness of amyloidosis and the availability of advanced treatment options. Growing emphasis on early diagnosis and expanding clinical trials are boosting adoption rates. Additionally, strong healthcare infrastructure, higher healthcare spending, and supportive reimbursement policies contribute to the country’s market dominance. The presence of leading pharmaceutical companies actively launching innovative therapies further accelerates market growth in the U.S.  

Europe Amyloidosis Treatment Market Insight

The European Amyloidosis Treatment market is expected to grow at a robust CAGR during the forecast period, driven by increasing awareness of amyloidosis and advancements in diagnostic and therapeutic technologies. Growing healthcare investments and supportive regulatory frameworks further enhance market expansion. Rising prevalence of hereditary and wild-type transthyretin amyloidosis, along with enhanced access to novel treatments, is boosting adoption across both urban and rural populations. Additionally, increased focus on early diagnosis and improved patient outcomes is fueling demand throughout Europe.

U.K. Amyloidosis Treatment Market Insight

The U.K. Amyloidosis Treatment market is projected to register a significant CAGR during the forecast period, fueled by rising adoption of smart home technologies and increasing demand for enhanced security and convenience. Growing concerns over burglary and personal safety are motivating homeowners and businesses to invest in keyless access solutions. Additionally, the U.K.’s strong digital infrastructure and widespread e-commerce adoption are further accelerating market growth.  

Germany Amyloidosis Treatment Market Insight

The German Amyloidosis Treatment market is projected to grow at a notable CAGR during the forecast period, driven by rising awareness of digital security and increasing demand for advanced, environmentally friendly solutions. Germany’s robust infrastructure and focus on innovation and sustainability support the widespread adoption of Amyloidosis Treatments in both residential and commercial sectors. Integration with home automation systems is also gaining traction, with consumers showing strong preference for secure, privacy-centric technologies that meet local expectations.  

Asia-Pacific Amyloidosis Treatment Market Insight

The Asia-Pacific Amyloidosis Treatment market is expected to register the fastest CAGR of over 24% in 2025, fueled by rapid urbanization, rising disposable incomes, and technological progress in key countries like China, Japan, and India. Government initiatives promoting digitalization and smart home adoption are accelerating market growth. Additionally, APAC’s emergence as a major manufacturing hub for Amyloidosis Treatment components is enhancing affordability and accessibility, broadening the consumer base across the region.  

Japan Amyloidosis Treatment Market Insight

The Japan Amyloidosis Treatment market is gaining traction due to the country’s advanced technology culture, rapid urbanization, and growing demand for convenience. Strong emphasis on security drives adoption, especially with the rise of smart homes and connected buildings. Integration with IoT devices like security cameras and lighting further fuels growth. Additionally, Japan’s aging population is expected to increase demand for user-friendly, secure access solutions across residential and commercial sectors.  

China Amyloidosis Treatment Market Insight

The China Amyloidosis Treatment market held the largest revenue share in the Asia-Pacific region in 2025, driven by rapid urbanization, a growing middle class, and widespread adoption of advanced technologies. As one of the largest smart home markets globally, China sees rising use of Amyloidosis Treatments across residential, commercial, and rental sectors. Government initiatives promoting smart cities, coupled with affordable solutions and strong domestic manufacturing, are major growth drivers.

Amyloidosis Treatment Market Share

The Amyloidosis Treatment industry is primarily led by well-established companies, including:

• Fortress Biotech, Inc. (U.S.)
• Takeda Pharmaceutical Company Ltd (Japan)
• Arcturus Therapeutics, Inc. (U.S.)
• Neurimmune (Switzerland)
• Pfizer Inc. (U.S.)
• Alnylam Pharmaceuticals, Inc. (U.S.)
• Proclara Biosciences (U.S.)
• Prothena (Ireland)
• Spectrum Pharmaceuticals, Inc. (U.S.)
• Ionis Pharmaceuticals, Inc. (U.S.
• Johnson & Johnson Services, Inc. (U.S.)
• Celgene Corporation (U.S.) (now part of Bristol Myers Squibb)
• Eidos Therapeutics (U.S.)
• GlaxoSmithKline plc (United Kingdom)
• Amgen Inc. (U.S.)
• Fresenius Kabi AG (Germany)
• Teva Pharmaceutical Industries Ltd (Israel)
• Mylan N.V. (U.S.) (merged with Upjohn to form Viatris)
• Novartis AG (Switzerland
• Boehringer Ingelheim International GmbH (Germany)

Latest Developments in Global Amyloidosis Treatment Market

• In October 2023, Alnylam Pharmaceuticals, Inc. announced the publication of results from APOLLO-B Phase 3 study of patisiran in patients with the cardiomyopathy of ATTR amyloidosis. The study reported that the patisiran preserved functionality capacity, health status, and quality of life compared with placebo at 12 months.

SKU-48048